Evidence map›Paper›PMID 22661511›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2012

Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion.

Mariane Abdillahi, Radha Ananthakrishnan, Srinivasan Vedantham, Linshan Shang, Zhengbin Zhu, Rosa Rosario, Hylde Zirpoli, Kurt M Bohren, Kenneth H Gabbay, Ravichandran Ramasamy

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Autophagy, a process within reperfusion injury: an update.International journal of clinical and experimental pathology · 2014
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mariane AbdillahiDiabetes Research Program, Department of Medicine, New York University Langone Medical Center, New York, USA.
Radha Ananthakrishnan
Srinivasan Vedantham
Linshan Shang
Zhengbin Zhu
Rosa Rosario
Hylde Zirpoli
Kurt M Bohren
Kenneth H Gabbay
Ravichandran Ramasamy
NYU Langone Health · USColumbia University Irving Medical Center · USChildren's Nutrition Research Center at Baylor College of Medicine · US

Funding

VASCULAR AND MONOCYTE DYSFUNCTION IN WOUND REPAIRP01HL060901 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 1999 to 2017
$20.2M
TRANSGENIC MOUSE AND ANIMAL MANAGEMENTP01AG026467 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHMIDT, ANN MARIE · 2008 to 2014
$9.2M
RAGE, Diabetes and Myocardial InfarctionR01HL102022 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN · 2010 to 2014
$2.2M
ALDOSE REDUCTASE AND CARDIAC ISCHEMIC INJURYR01HL061783 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RAMASAMY, RAVICHANDRAN · 1999 to 2006
$1.9M
NHLBI NIH HHS HL-102022NHLBI NIH HHS HL-60901NHLBI NIH HHS HL-61783NIA NIH HHS AG-026467
6 · The paper itself

Abstract

Earlier studies have demonstrated that aldose reductase (AR) plays a key role in mediating ischemia-reperfusion (I/R) injury. Our objective was to investigate if AR mediates I/R injury by influencing phosphorylation of glycogen synthase kinase-3β (p-GSK3β). To investigate this issue, we used three separate models to study the effects of stress injury on the heart. Hearts isolated from wild-type (WT), human expressing AR transgenic (ARTg), and AR knockout (ARKO) mice were perfused with/without GSK3β inhibitors (SB-216763 and LiCl) and subjected to I/R. Ad-human AR (Ad-hAR)-expressing HL-1 cardiac cells were exposed to hypoxia (0.5% O(2)) and reoxygenation (20.9% O(2)) conditions. I/R in a murine model of transient occlusion and reperfusion of the left anterior descending coronary artery (LAD) was used to study if p-GSK3β was affected through increased AR flux. Lactate dehydrogenase (LDH) release and left ventricular developed pressure (LVDP) were measured. LVDP was decreased in hearts from ARTg mice compared with WT and ARKO after I/R, whereas LDH release and apoptotic markers were increased (P < 0.05). p-GSK3β was decreased in ARTg hearts compared with WT and ARKO (P < 0.05). In ARKO, p-GSK3β and apoptotic markers were decreased compared with WT (P < 0.05). WT and ARTg hearts perfused with GSK3β inhibitors improved p-GSK3β expression and LVDP and exhibited decreased LDH release, apoptosis, and mitochondrial pore opening (P < 0.05). Ad-hAR-expressing HL-1 cardiac cells, exposed to hypoxia (0.5% O(2)) and reoxygenation (20.9% O(2)), had greater LDH release compared with control HL-1 cells (P < 0.05). p-GSK3β was decreased and correlated with increased apoptotic markers in Ad-hAR HL-1 cells (P < 0.05). Treatment with phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) inhibitor increased injury demonstrated by increased LDH release in ARTg, WT, and ARKO hearts and in Ad-hAR-expressing HL-1 cells. Cells treated with protein kinase C (PKC) α/β inhibitor displayed significant increases in p-Akt and p-GSK3β expression, and resulted in decreased LDH release. In summary, AR mediates changes in p-GSK3β, in part, via PKCα/β and Akt during I/R.

Indexed as

Aldehyde ReductaseAnimalsApoptosisCell LineDisease Models, AnimalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMyocardial Reperfusion InjuryMyocytes, CardiacPhosphatidylinositol 3-KinaseAldehyde ReductaseGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mousePhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPRKCA protein, humanProtein Kinase CProtein Kinase C-alphaProtein Kinase C betaProtein Kinase InhibitorsProto-Oncogene Proteins c-akt

Identifiers

PMID22661511
PMCPMC3423166
OpenAlexW2096305380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.